Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
In their two year study they found that there were no differences in changes in bone density or menopausal symptoms between women taking soy and those taking a placebo, although women taking isoflavones did have more hot flashes, Dr. Silvina Levis of the University of Miami and colleagues reported in the August 8/22 issue of Archives of Internal Medicine.
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay.
Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.
UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously.
Flaxseed has been the latest agent that has been tried in treating menopausal hot flashes and it is seen that it does not reduce the incidence of the unpleasant symptoms.
Men with prostate cancer are at higher risk of developing diabetes or diabetes risk factors if they receive androgen deprivation therapy (ADT) to block the production or action of male hormones that can fuel the growth of this cancer.
Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4.
Women who choose among different breast cancer treatment options make smarter choices when getting the information and making decisions in small doses rather than all at once, as is customary, a University of Michigan study found.
Researchers from Canada and the United States today told attendees of the Experimental Biology 2011 Scientific Meeting that they have uncovered a possible means of enabling women to favorably influence whether the estrogens in their bodies take a "beneficial path" or a "disease-potential" path.
According to a new study hormone therapy may not be as risky for elder women as earlier thought. This comes from the Women's Health Initiative, a federally funded trial that tracked thousands of women taking hormones or placebo pills for years. The WHI looked at women who have had hysterectomies or have had their uterus removed and thus can take estrogen unaccompanied by another hormone, progestin. It found that a heightened risk of stroke from taking estrogen faded with time, while a reduced risk of breast cancer held steady.
A Hunter-based prostate cancer support group says ground-breaking research by the University of Newcastle will help save many lives in the region. This new work has found patients with localized advanced prostate cancer can double their chances of survival by undertaking hormone therapy in combination with radiology treatment. This comes from a 10 year trial, coordinated by the University's Professor Jim Debnam.
Many survivors of breast cancer cite stress as a link to the cancer despite no scientific proof of a connection. Experts believe that the root cause here are the lifestyle-related issues - such as smoking and obesity - where there is a clear link to the cancer.
Genomic Health, Inc. today announced results from nine studies utilizing the Oncotype DX test in early-stage breast cancer patients at the 12th Annual St. Gallen International Breast Cancer Conference in St. Gallen, Switzerland.
Starting hormone therapy at around the time of menopause is associated with a greater risk of breast cancer compared to starting after a longer gap, according to a study published online Jan. 28 in The Journal of the National Cancer Institute.
Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.
Older men with high-risk prostate cancer frequently are offered fewer - and less effective - choices of treatment than younger men, potentially resulting in earlier deaths, according to a new UCSF study.
"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Shak, MD, chief medical officer of Genomic Health.
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.
A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.